Trial Profile
A Randomized Phase 3 Study of LY2835219 Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms JUNIPER
- Sponsors Eli Lilly and Company; Eli Lilly Japan
- 18 Jan 2024 Planned End Date changed from 20 Sep 2023 to 31 Dec 2024.
- 08 Aug 2022 Planned End Date changed from 20 Sep 2022 to 20 Sep 2023.
- 10 Mar 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.